Lixte Biotechnology Holdings, Inc. Finalizes $4.3 Million Registered Direct Offering for Cancer Treatments
Lixte Biotechnology Holdings, Inc., a biotech company specializing in cancer treatments, has recently finalized agreements with accredited investors for a registered direct offering. The offering includes the sale of approximately $4.3 million worth of Common Stock and pre-funded and investor warrants at a price of $4.09 per Common Unit. The transaction adheres to Nasdaq rules and is expected to close around December 19, 2025, pending customary closing conditions.
The offering comprises 1,051,342 Common Units (or Pre-Funded Units), each consisting of a share of Common Stock or a Pre-Funded Warrant and a Common Warrant to purchase a share of Common Stock at an exercise price of $3.96. The Pre-Funded Warrants are immediately exercisable and can be exercised until fully utilized. The Common Warrants have an initial exercise price of $3.96 per share and expire 60 months after the issuance date.
The Company anticipates receiving aggregate gross proceeds of approximately $4.3 million from the offering. These funds, combined with existing cash, will be utilized for general corporate purposes and working capital. Spartan Capital Securities, LLC, is the exclusive placement agent for the offering, with legal counsel provided by Sichenzia Ross Ference Carmel LLP for the Company and Kaufman & Canoles, P.C. for Spartan Capital Securities LLC.
This registered direct offering is conducted under an effective shelf registration statement on Form S-3 (No. 333-278874) previously approved by the U.S. Securities and Exchange Commission (SEC). A final prospectus supplement and accompanying prospectus detailing the offering's terms will be filed with the SEC and made available on their website. Interested parties can obtain electronic copies of the documents by contacting Spartan Capital Securities LLC.
In conclusion, Lixte Biotechnology Holdings, Inc. has successfully secured a registered direct offering with accredited investors, raising approximately $4.3 million for advancing cancer treatments. The Company's strategic use of these funds for general corporate purposes and working capital underscores its commitment to furthering innovative solutions in the biotech industry.